Phase I/II Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Patients With Selected Advanced Solid Tumor Malignancies, including Pancreatic Cancer
Summary
The purpose of this phase I/II open-label, sequential-group, dose-escalation and cohort-expansion study is to evaluate the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of Zotatifin (eFT226) in patients with selected advanced solid tumor malignancies, including pancreatic cancer.
General Information
NCT#: NCT04092673
Study ID: eFT226-0002
Trial Phase: Phase I/II
Trial Sponsor: Effector Therapeutics
Therapies Used in This Trial: Zotatifin